# Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy

> **NCT05443178** · PHASE1 · RECRUITING · sponsor: **University of Zurich** · enrollment: 16 (estimated)

## Conditions studied

- Tuberculosis Infection

## Interventions

- **DRUG:** Nivaquine ® (Chloroquine)

## Key facts

- **NCT ID:** NCT05443178
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-04
- **Primary completion:** 2024-10-04
- **Final completion:** 2025-06-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443178, "Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05443178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*